[{"id":"b9a406bd-d975-4b31-a433-86da8522fc92","acronym":"TAS-120-202","url":"https://clinicaltrials.gov/study/NCT04189445","created_at":"2021-01-19T19:00:59.221Z","updated_at":"2025-02-25T16:44:46.191Z","phase":"Phase 2","brief_title":"Futibatinib in Patients With Specific FGFR Aberrations","source_id_and_acronym":"NCT04189445 - TAS-120-202","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 amplification • FGFR1 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 amplification • FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 11/11/2024","primary_completion_date":" 11/11/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-05"},{"id":"c8879055-5cfc-4980-bb0d-ebf82077c424","acronym":"FOENIX-MBC2 TAS-120-201","url":"https://clinicaltrials.gov/study/NCT04024436","created_at":"2021-01-18T19:45:26.836Z","updated_at":"2024-07-02T16:35:00.592Z","phase":"Phase 2","brief_title":"A Study of TAS-120 in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT04024436 - FOENIX-MBC2 TAS-120-201","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" HER-2 • PD-L1 • FGFR2","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • FGFR1 amplification • FGFR2 amplification","tags":["HER-2 • PD-L1 • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • FGFR1 amplification • FGFR2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Lytgobi (futibatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 08/30/2019","start_date":" 08/30/2019","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 07/05/2024","study_completion_date":" 07/05/2024","last_update_posted":"2024-05-29"},{"id":"94fc3ab5-0532-4f36-b807-3064b8e380bd","acronym":"FIGHT","url":"https://clinicaltrials.gov/study/NCT03694522","created_at":"2021-01-17T17:12:46.809Z","updated_at":"2024-07-02T16:35:17.364Z","phase":"Phase 2","brief_title":"A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT03694522 - FIGHT","lead_sponsor":"Five Prime Therapeutics, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 amplification • FGFR2 overexpression • FGFR2b overexpression","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 amplification • FGFR2 overexpression • FGFR2b overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)"],"overall_status":"Completed","enrollment":" Enrollment 155","initiation":"Initiation: 09/14/2018","start_date":" 09/14/2018","primary_txt":" Primary completion: 09/23/2020","primary_completion_date":" 09/23/2020","study_txt":" Completion: 05/13/2022","study_completion_date":" 05/13/2022","last_update_posted":"2024-02-28"},{"id":"79f91b60-669d-47f6-83fb-b95eccd77343","acronym":"NIVOFGFR2","url":"https://clinicaltrials.gov/study/NCT05859477","created_at":"2023-05-16T17:06:20.563Z","updated_at":"2024-07-02T16:35:24.858Z","phase":"Phase 2","brief_title":"Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer","source_id_and_acronym":"NCT05859477 - NIVOFGFR2","lead_sponsor":"Kidney Cancer Research Bureau","biomarkers":" HER-2 • PD-L1 • FGFR2","pipe":" | ","alterations":" HER-2 negative • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression","tags":["HER-2 • PD-L1 • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • capecitabine • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 06/05/2022","start_date":" 06/05/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-01"},{"id":"2b64af10-d65b-4d9e-b123-5cd01fb9300a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05627063","created_at":"2022-11-25T15:58:10.134Z","updated_at":"2024-07-02T16:35:38.335Z","phase":"Phase 1","brief_title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05627063","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR3 S249C • FGFR2 rearrangement • FGFR3 Y373C • FGFR3 G370C • FGFR3 R248C","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR3 S249C • FGFR2 rearrangement • FGFR3 Y373C • FGFR3 G370C • FGFR3 R248C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABSK121"],"overall_status":"Recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 03/15/2025","primary_completion_date":" 03/15/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-09-01"},{"id":"484ddfbb-7589-4666-ae34-6a1cb206f2f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05019794","created_at":"2021-08-25T14:53:06.567Z","updated_at":"2024-07-02T16:36:08.254Z","phase":"Phase 2a","brief_title":"Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations","source_id_and_acronym":"NCT05019794","lead_sponsor":"LianBio LLC","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 amplification","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truseltiq (infigratinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/13/2020","start_date":" 05/13/2020","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2022-06-27"},{"id":"49735e15-4e3d-4d13-9289-8b33e13bc467","acronym":"","url":"https://clinicaltrials.gov/study/NCT02691767","created_at":"2021-03-25T18:46:08.042Z","updated_at":"2024-07-02T16:36:08.681Z","phase":"","brief_title":"Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors","source_id_and_acronym":"NCT02691767","lead_sponsor":"Samsung Medical Center","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 amplification","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 01/16/2018","primary_completion_date":" 01/16/2018","study_txt":" Completion: 02/13/2020","study_completion_date":" 02/13/2020","last_update_posted":"2022-06-15"},{"id":"aec26925-41ed-4f2f-9267-a32e6531e375","acronym":"","url":"https://clinicaltrials.gov/study/NCT02450136","created_at":"2022-06-02T19:55:13.662Z","updated_at":"2024-07-02T16:36:08.673Z","phase":"","brief_title":"Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors","source_id_and_acronym":"NCT02450136","lead_sponsor":"Samsung Medical Center","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 amplification","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 10/08/2015","start_date":" 10/08/2015","primary_txt":" Primary completion: 07/30/2017","primary_completion_date":" 07/30/2017","study_txt":" Completion: 02/01/2018","study_completion_date":" 02/01/2018","last_update_posted":"2022-06-15"},{"id":"d4d894ac-2658-4499-8ad7-5be03852e67a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05173142","created_at":"2021-12-29T13:53:45.797Z","updated_at":"2025-02-25T14:52:10.343Z","phase":"Phase 1/2","brief_title":"HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors","source_id_and_acronym":"NCT05173142","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" FGFR","pipe":" | ","alterations":" PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • fanregratinib (HMPL-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 141","initiation":"Initiation: 01/22/2022","start_date":" 01/22/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-03-08"},{"id":"0e3f138d-c251-4f5f-bf20-dceb29690abf","acronym":"","url":"https://clinicaltrials.gov/study/NCT01719549","created_at":"2021-01-18T07:30:00.354Z","updated_at":"2025-02-25T15:40:29.402Z","phase":"Phase 2","brief_title":"Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1","source_id_and_acronym":"NCT01719549","lead_sponsor":"Asan Medical Center","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 amplification","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dovitinib (TKI258)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 09/01/2012","start_date":" 09/01/2012","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2020-01-07"},{"id":"4e06d46a-253b-484d-a0a2-bca662c63ece","acronym":"","url":"https://clinicaltrials.gov/study/NCT01004224","created_at":"2021-01-17T17:13:53.960Z","updated_at":"2024-07-02T16:36:54.872Z","phase":"Phase 1","brief_title":"A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT01004224","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FGFR2 • FGFR3","pipe":" | ","alterations":" FGFR1 amplification • FGFR2 mutation • FGFR2 amplification • FGFR3 mutation • FGFR3 amplification","tags":["FGFR2 • FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 amplification • FGFR2 mutation • FGFR2 amplification • FGFR3 mutation • FGFR3 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truseltiq (infigratinib)"],"overall_status":"Completed","enrollment":" Enrollment 208","initiation":"Initiation: 12/11/2009","start_date":" 12/11/2009","primary_txt":" Primary completion: 10/08/2018","primary_completion_date":" 10/08/2018","study_txt":" Completion: 10/08/2018","study_completion_date":" 10/08/2018","last_update_posted":"2019-10-04"},{"id":"5ac6cf9e-efcf-436f-8803-ff8e9e904ab6","acronym":"RPT835GC1B","url":"https://clinicaltrials.gov/study/NCT04071184","created_at":"2021-01-18T19:55:52.106Z","updated_at":"2024-07-02T16:36:55.182Z","phase":"Phase 1b","brief_title":"Study of Alofanib in Patients With Metastatic Gastric Cancer","source_id_and_acronym":"NCT04071184 - RPT835GC1B","lead_sponsor":"Russian Pharmaceutical Technologies","biomarkers":" FGFR2 • FRS2","pipe":" | ","alterations":" FGFR2 fusion • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression","tags":["FGFR2 • FRS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alofanib (RPT835)"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 05/26/2019","start_date":" 05/26/2019","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2019-09-26"}]